Longeveron Inc. (LGVN)
| Market Cap | 21.96M -16.1% |
| Revenue (ttm) | 1.20M -49.9% |
| Net Income | -22.70M |
| EPS | -1.29 |
| Shares Out | 29.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 559,610 |
| Open | 0.8500 |
| Previous Close | 0.8379 |
| Day's Range | 0.7500 - 0.8625 |
| 52-Week Range | 0.4750 - 1.8000 |
| Beta | -0.32 |
| Analysts | Strong Buy |
| Price Target | 5.50 (+633.24%) |
| Earnings Date | May 13, 2026 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated... [Read more]
Financial Performance
In 2025, Longeveron's revenue was $1.20 million, a decrease of -49.87% compared to the previous year's $2.39 million. Losses were -$22.70 million, -7.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for LGVN stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 633.24% from the latest price.
News
Longeveron reports DMC approval for laromestrocel study to continue as designed
Longeveron (LGVN) announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial evaluating...
Longeveron downgraded to Hold from Buy at Maxim
Maxim downgraded Longeveron (LGVN) to Hold from Buy.
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment...
Longeveron provides update on laromestrocel development after Type C meeting
Longeveron (LGVN) announced that a constructive Type C meeting with the FDA was held in late March, with the FDA providing their meeting summary in late April, to discuss the…
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agin...
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relate...
Longeveron price target lowered to $8 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Longeveron (LGVN) to $8 from $10 and keeps a Buy rating on the shares. The firm cites equity dilution for the target…
Longeveron files to sell 30.87M shares of Class A common stock for holders
16:04 EDT Longeveron (LGVN) files to sell 30.87M shares of Class A common stock for holders
Longeveron granted Chinese patent for potency assay methods
Longeveron (LGVN) announced that the China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells derived from bon...
Longeveron granted Chinese patent for potency assay methods
Longeveron (LGVN) announced that the China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells derived from bon...
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).
Longeveron price target lowered to $2 from $3 at Roth Capital
Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $2 from $3 but keeps a Buy rating on the shares. The firm continues to expect top-line data from…
Longeveron Earnings Call Transcript: Q4 2025
Secured $15M in new capital, extending cash runway into Q4 2026, while advancing pivotal HLHS and PDCM trials. Revenue fell 50% year-over-year, and net loss widened to $22.7M, but strategic partnerships and PRV opportunities could drive future growth.
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.
Longeveron Announces Closing of Private Placement of up to $30 Million
$15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market ...
3 Penny Stocks to Watch Now, 3/11/26
Agape ATP ($ATPC), Longeveron ($LGVN), and MiNK Therapeutics ($INKT) are the 3 Penny Stocks to watch on March 11, based on TipRanks’ Penny Stock Screener tool. These stocks are usually priced at $5…
Longeveron prices 6.01M shares at 52c in private placement
Longeveron (LGVN) entered into a definitive agreement with certain institutional and accredited investors for up to approximately $30M in gross proceeds through a private placement, priced at-the-mark...
Longeveron: Phase 2b results show laromestrocel improved physical condition
Longeveron (LGVN) announced that results of its Phase 2b clinical trial were published today in Cell Stem Cell, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel,…
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.
Longeveron names Stephen Willard as CEO, succeeding Than Powell
Longeveron (LGVN) announced that the company’s Board of Directors has appointed Stephen Willard as CEO, effective February 11. He succeeds Than Powell who served as interim CEO prior to the…
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant ...
Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage
Longeveron (LGVN) supports and applauds Congress passing the Mikaela Naylon Give Kids a Chance Act. The Mikaela Naylon Give Kids a Chance Act reauthorizes the Rare Pediatric Disease Priority Review…
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.
Longeveron granted Japan patent for potency assay methods for MSCs
Longeveron (LGVN) announced that the Japan Patent Office, JPO, has granted a patent covering potency assay methods for assessing human mesenchymal stem cells, MSCs, derived from bone marrow, adipose t...
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs,...